iBio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
38.9%projected annual EPS growth
Analyst Coverage
8analysts covering
FY Revenue (est.)
$142.9Knext fiscal year
FY EPS (est.)
-$0.33next fiscal year
Monitoring Framework
Key Performance Indicators
Dosing of First Participant in IBIO-600 Phase 1 Trial Quarterly1.0
Cash Runway Extension Quarterly2KTarget: Q4 Fiscal Year 2028
IBIO-610 Preclinical Visceral Fat Reduction Annually6.7Target: 6.7% or higher
Watch Items
- Clinical Trial Progress of IBIO-600 in AustraliaTrigger: Dosing of first cohort and initial safety data readoutAction: Evaluate safety profile and dose-escalation parameters to confirm therapeutic window.
- R&D and G&A Expense Burn RateTrigger: Quarterly cash burn exceeding $10 millionAction: Review pipeline prioritization and assess potential need for additional non-dilutive or dilutive financing.
- Preclinical Progress of IBIO-610 (Activin E Antibody)Trigger: Completion of IND-enabling toxicology studies by late 2026Action: Prepare and submit IND application to transition IBIO-610 into Phase 1 clinical trials by early 2027.
Research as of 19 Jun 2026